Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Print  

Study Name: Effect of Sulforaphane in Broccoli Sprouts on Nrf2 activation
Study Type: Interventional
Intervention Category: Nutritional-GI Therapies
Study Sponsor: Chmiel, James

Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Study Phase: Other
Recruitment Status: Trial Completed
Study Drug(s): Not Applicable
Number of Participants Being Recruited: 15
Single / Multi-Center: Single Center
STUDY BACKGROUND INFORMATION:
Inflammation is an important factor in the pathophysiology of cystic fibrosis. The intracellular pathway, Nrf2, is important in the body's inflammatory response and has been shown to be deficient in CF cells. This trial looked at the whether consuming well chewed broccoli sprouts which releases sulforaphane activates the Nrf2 pathway. This was an 8 day trial where the study participant ate well - chewed broccoli sprouts. Specimens of blood, urine, and nasal epithelial samples will be taken during the trial.
ELIGIBILITY
Age: 18 Years - 49 Years
FEV1: Not Applicable
P. aeruginosa status: Not applicable
B. cepacia status: Not applicable
Other Primary Eligibility Requirements:

Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
FOR MORE INFORMATION:
Sponsor Contact Information:
Trial Specific Link on ClinicalTrials.gov: Not Available
Clinical Research Terms Glossary: Click here
TRIAL RESULTS:
Primary Efficacy:

Ten healthy volunteers and 5 subjects with CF received 100 gms of broccoli sprouts daily for 5 days. Endpoints to determine whether sulforaphane in the broccoli sprouts would reduce white cells (PMNs) in both groups were measured. Mean change in log10 PMNs did not differ between the two groups. There were no other significant differences in other measures. A significantly higher baseline urine bromotyrosine was seen in subjects with CF compared to healthy volunteers.

Secondary Efficacy:

Not applicable

Safety:

No serious adverse events occurred during the study.

The summary of data provided here is from a poster presented at the Cystic Fibrosis Foundation North American CF Conference (2012). These data may be preliminary and have not been peer-reviewed.

Citation:

Not Available
Back to top